MaxCyte Total Revenue

As of the most recent data (March 2026), MXCT shows a total revenue of $32M. That compares with $38M in the prior-year period — down 14.3% year over year. That is below the Materials sector average of $430B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MXCT's total revenue is now $32M (was $38M) — a 14.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether MaxCyte is outperforming or lagging.

The Materials sector average total revenue is about $430B. MaxCyte is at $32M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how MXCT stacks up against individual peers as well.

Tracking MXCT's total revenue over time shows whether MaxCyte is scaling, shrinking, or reshaping that part of the business. The current reading is $32M That compares with $38M in the prior-year period — down 14.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total revenue page, Stockcircle has MaxCyte's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $32M) with ownership activity and broader fundamentals.